Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Genmab A/S
  6. News
  7. Summary
    GMAB   DK0010272202

GENMAB A/S

(GMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Genmab A/S : Transactions in connection with share buy-back program (Form 6-K)

06/21/2021 | 09:39am EDT

Transactions in connection with share buy-back program

Company Announcement

COPENHAGEN, Denmark; June 21, 2021 - Genmab A/S (Nasdaq: GMAB). On February 23, 2021 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant exercises and to honor our commitments under our Restricted Stock Units program.

The share buy-back program is expected to be completed no later than June 30, 2021 and comprises up to 200,000 shares.

The following transactions were executed under the program from June 14, 2021, to June 18, 2021:

No. of shares

Average price (DKK)

Total value (DKK)

Accumulated through last announcement

174,400

378,392,082

June 14, 2021

1,700

2,685.57

4,565,469

June 15, 2021

1,000

2,704.40

2,704,400

June 16, 2021

June 17, 2021

1,000

1,800

2,702.76

2,690.94

2,702,760

4,843,692

June 18, 2021

1,900

2,727.94

5,183,086

Total

7,400

19,999,407

Accumulated under the program

181,800

398,391,489

Details of each transaction are included as an appendix to this announcement.

Following these transactions, Genmab holds 281,006 shares as treasury shares, corresponding to 0.43% of the total share capital and voting rights.

The share buy-back program is undertaken in accordance with Regulation (EU) No. 596/2014 ('MAR') and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the 'Safe Harbour Regulation.' Further details on the terms of the share buy-back program can be found in our company announcement no. 11 dated February 23, 2021.

About Genmab

Genmab is an international biotechnology company with a core purpose to improve the lives of patients with cancer. Founded in 1999, Genmab is the creator of multiple approved antibody therapeutics that are marketed by its partners. The company aims to create, develop and commercialize differentiated therapies by leveraging next-generation antibody technologies, expertise in antibody biology, translational research and data sciences and strategic partnerships. To create novel therapies, Genmab utilizes its next-generation antibody technologies, which are the result of its collaborative company culture and a deep passion for innovation. Genmab's proprietary pipeline consists of modified antibody candidates, including bispecific T-cell engagers and next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. The company is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com.

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 52

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 1/2

21560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Transactions in connection with share buy-back program

Contact:
Marisol Peron, Senior Vice President, Global Investor Relations & Communications

T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations:

Andrew Carlsen, Vice President, Head of Investor Relations

T: +45 3377 9558; E: acn@genmab.com


This Company Announcement contains forward looking statements. The words 'believe', 'expect', 'anticipate', 'intend' and 'plan' and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.


Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®;HexaBody in combination withthe HexaBody logo®; DuoHexaBody® and HexElect®.

Genmab A/S

Tel: +45 7020 2728

Company Announcement no. 52

Kalvebod Brygge 43

Fax: +45 7020 2729

Page 2/2

21560 Copenhagen V, Denmark

www.genmab.com

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Disclaimer

Genmab A/S published this content on 21 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 June 2021 13:38:05 UTC.


ę Publicnow 2021
All news about GENMAB A/S
08/04PRESS RELEASE : BioNTech Completes Acquisition of Kite's Neoantigen TCR Cell The..
DJ
08/02PRESS RELEASE : BioNTech to Report Second Quarter Financial Results and Operatio..
DJ
07/26PRESS RELEASE : BioNTech Provides Update on Plans to Develop Sustainable Solutio..
DJ
07/23PRESS RELEASE : Pfizer And BioNTech to Supply U.S. -2-
DJ
07/22GENMAB A/S : Major shareholder announcement for Genmab A/S
AQ
07/22JOHNSON & JOHNSON : Genmab Announces Net Sales of DARZALEX (daratumumab) for the..
AQ
07/21Major Shareholder Announcement
GL
07/21GENMAB A/S : receives royalties on worldwide net sales from Janssen Biotech, Inc..
PU
07/21GENMAB A/S : Says Darzalex Sales in Q2 Hit $1.43 Billion
MT
07/21PRESS RELEASE : Pfizer and BioNTech Announce -3-
DJ
More news
Financials
Sales 2021 7 684 M 1 224 M 1 224 M
Net income 2021 2 145 M 342 M 342 M
Net cash 2021 15 063 M 2 399 M 2 399 M
P/E ratio 2021 96,0x
Yield 2021 -
Capitalization 192 B 30 501 M 30 503 M
EV / Sales 2021 23,0x
EV / Sales 2022 17,1x
Nbr of Employees 871
Free-Float 95,1%
Chart GENMAB A/S
Duration : Period :
Genmab A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENMAB A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 2 930,00 DKK
Average target price 2 499,22 DKK
Spread / Average Target -14,7%
EPS Revisions
Managers and Directors
Jan G. J. van de Winkel President & Chief Executive Officer
Anthony Pagano Chief Financial Officer & Executive Vice President
Deirdre P. Connelly Chairman
Tahamtan Ahmadi Chief Medical Officer & Executive Vice President
Anthony Mancini Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
GENMAB A/S18.96%30 483
BIONTECH SE408.39%100 096
GILEAD SCIENCES, INC.19.86%86 839
WUXI APPTEC CO., LTD.43.36%72 049
REGENERON PHARMACEUTICALS21.40%60 161
VERTEX PHARMACEUTICALS-15.55%51 779